tbuckley/cabot-search huggingface dataset:
Characterization of CD4+ T Cell Response Induced by p210-Derived Peptide Vaccinations in CML Patients.
Authors: Monica Bocchia, Micaela Ippoliti, Elisabetta Abruzzese, Maristella Tassi, Marzia Defina, Malgorzata M. Trawinska, Alessandro Gozzetti, Donatella Raspadori, Francesco Lauria
Journal: Blood (2007)
Prognostic Value of Minimal Residual Disease Assessed By WT1 Expression Level and Flow Cytometry in Acute Myeloid Leukemia Patients Undergoing Allogeneic Marrow Transplantation
Authors: Livia Giannoni, Fabio Guolo, Paola Minetto, Federica Galaverna, Chiara Ghiggi, Marino Clavio, Samuele Bagnasco, Carmen Di Grazia, Raffaella Grasso, Nicoletta Colombo, Daniele Avenoso, Giordana Pastori, Filippo Ballerini, Annalisa Kunkl, Maurizio Miglino, Roberto Lemoli, Marco Gobbi, Andrea Bacigalupo
Journal: Blood (2014)
Inhibition of Tak-1 by AZ-Tak1 Impairs NF-κB Activation, Downregulates XIAP and Activates Caspase-9 Inducing Apoptosis In Mantle Cell lymphoma
Authors: Daniela Buglio, Sangeetha Palakurti, Francisco Vega, Sattva S. Neelapu, Donald Berry, Yuan Ji, Kate Byth, Anas Younes
Journal: Blood (2010)
Effects of Cord Blood Cell Subset Populations in the Development of the Dominant Cord Blood Unit in Non-Myeloablative Sequential Double Cord Blood Transplantation (DCBT).
Authors: David T. Ting, Karen Ballen, Thomas R. Spitzer, Richard L. Haspel, Michelle Dorn, Fred Preffer, Vassiliki Boussiotis, Steven McAfee, Eyal Attar, Joseph H. Antin, Robert J. Soiffer, Corey Cutler, Vincent Ho, Bimalangshu R. Dey
Journal: Blood (2006)
Clinical Results in Patients with Primary and Secondary Myelofibrosis Treated with Monthly Cycles of Oral Melphalan.
Authors: Ida Carmosino, Roberto Latagliata, Massimo Breccia, Laura Cannella, Federico Vozella, Paola Volpicelli, Michelina Santopietro, Antonio Spadea, Maria Concetta Petti, Giuliana Alimena
Journal: Blood (2009)
The Cytokine Polymorphisms Affect the Severity of Thrombocytopenia at Diagnosis in Chronic Immune Thrombocytopenia.
Authors: Takayuki Saitoh, Chiaki Ushie, Atsushi Iwasaki, Norihiko Moriyama, Tomonori Takani, Hattori Hikaru, Hiroshi Handa, Hiromi Koiso, Akihiko Yokohama, Norifumi Tsukamoto, Hatsue Ogawara, Hirokazu Murakami
Journal: Blood (2012)
Genomic Regions Supporting microRNA Expression and Their Biogenesis Are Globally Conserved in Diffuse Large B-Cell Lymphomas (DLBCL) and Display a Limited Number of Homozygous Deletions or Amplifications.
Authors: Fabrice Jardin, Philippe Ruminy, Jean-Pierre Kerckaert, Martin Figeac, Philippe Bertrand, Francoise Parmentier, Jean-Michel Picquenot, Gerard Buchonnet, Christian Bastard, Herve Tilly
Journal: Blood (2007)
AC220, a Potent, Selective, Second Generation FLT3 Receptor Tyrosine Kinase (RTK) Inhibitor, in a First-in-Human (FIH) Phase 1 AML Study.
Authors: Jorge Cortes, James Foran, Darejan Ghirdaladze, Marcel P DeVetten, Mamia Zodelava, Peter Holman, Mark J Levis, Hagop M Kantarjian, Gautam Borthakur, Joyce James, Patrick P Zarringkar, Ruwanthi N Gunawardane, Robert C Armstrong, Norman M Padre, Wendell Wierenga, Robert Corringham, Mohit Trikha
Journal: Blood (2009)
Abstract #1718: Dimethylaminoparthenolide targets apoptotic machinery in glioblastoma through ROS generation and NF\#954;B inhibition
Authors: Rajasubramaniam Shanmugam, Zhu Wei, Peter Crooks, Harikrishna Nakshatri, Chrsistopher Sweeney
Journal: Cancer Research (2009)

Gliobastoma is the most common malignant brain tumor in humans and it causes approximately 11,000 deaths among 18,500 new cases per year in the United States. Gliobastoma is associated with a median survival of less than 12 months with a   Citation Information: In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 1718.
Protein Inhibitor of Coagulation Factor Xa (PifXa): A New Protein-Based Specific Factor Xa Inhibitor Is An Effective, Reversible Inhibitor of Blood Coagulation.
Authors: Mette Sondrup Andersen, Aage Kristian Olsen Alstrup, Julie Kirstine Andersen, Søren Risom Kristensen, Kåre Lehmann Nielsen
Journal: Blood (2010)
Aprepitant (Emend®) Significantly Increases Sirolimus Levels In Patients Undergoing Allogeneic Hematopoietic Stem Cell transplantation.
Authors: Sepideh Shayani, Joycelynne Palmer, Tracey Stiller, Chan Holly, Svetlana Keuylian, Pablo Miguel Parker, Stephen Forman, Ryotaro Nakamura
Journal: Blood (2010)
Efficacy of a 3-Day, Low-Dose Treatment with 5-Azacytidine Followed by Donor Lymphocyte Infusions (DLI ) in Older AML/MDS Patients Relapsed after Allografting.
Authors: Michael Lübbert, Ralph M. Waesch, Reinhard Marks, Björn Rüter, Hartmut Bertz, Juergen Finke
Journal: Blood (2008)
Expression of Interleukin-7 Receptor and Activation Markers on Central Memory CD8 Cells in HIV-Infected Individuals Treated with Antiretrovirals.
Authors: Jean Pierre Routy, Med-Rachid Boulassel, Francois Mercier, Chantal Grignon, Mavis Young, Mario Legault, Cecile Tremblay, Remi Cheynier, Rafick-Pierre Sekaly
Journal: Blood (2005)
A Retrospective Evaluation of the Effects of Severe Aplastic Anemia Treatment in Children with Horse and Rabbit ATG.Polish Pediatric Hematology Group
Authors: Katarzyna Pawelec, Michal Matysiak, Malgorzata Salamonowicz, Jerzy Kowalczyk, Walentyna Balwierz, Ewa Zaleska-Czepko, Alicja Chybicka, Krzysztof Szmyd, Tomasz Szczepanski, Halina Bubala, Mariusz Wysocki, Andrzej Kurylak, Jacek Wachowiak, Dawid Szprecht, Wojciech Mlynarski, Monika Bulas, Maryna Krawczuk-Rybak, Elzbieta Leszczynska, Tomasz Urasinski, Jaroslaw Peregud-Pogorzelski, Anna Balcerska, Barbara Kaczorowska
Journal: Blood (2011)
Translational Focus on Targeting HDAC6 with Ricolinostat Confirms Potent Activity in Preclinical Models of Lymphoma and a Favorable Toxicity Profile in Patients with Relapsed or Refractory Lymphoma
Authors: Jennifer E Amengual, Lichtenstein Renee, Celeste Rojas, Kelly Zullo, Maximilian Lombardo, Emily Lichtenstein, Ellen Neylon, Changchun Deng, Ahmed Sawas, Bijal D Shah, Catherine Wheeler, Simon S Jones, Owen A. O'Connor
Journal: Blood (2015)
Inhibition of Wnt/β-Catenin Signaling by AV65 Treatment Caused Cell Cycle Arrest and Induced Caspase-Independent or -Dependent Apoptosis in CML Cells.
Authors: Rina Nagao, Eishi Ashihara, Shinya Kimura, Hisayuki Yao, Miki Takeuchi, Asumi Yokota, Ruriko Tanaka, Hideyo Hirai, Jeffrey W Strovel, Janak Padia, Wieslaw M Cholody, Taira Maekawa
Journal: Blood (2009)
Therapeutic implications of cellular and molecular biology of cancer stem cells in melanoma
Authors: Dhiraj Kumar, Mahadeo Gorain, Gautam Kundu, Gopal C. Kundu
Journal: Molecular Cancer (2017)

Melanoma is a form of cancer that initiates in melanocytes. Melanoma has multiple phenotypically distinct subpopulation of cells, some of them have embryonic like plasticity which are involved in self-renewal, tumor initiation, metastasis and progression and provide reservoir of therapeutically resistant cells. Cancer stem cells (CSCs) can be identified and characterized based on various unique cell surface and intracellular markers. CSCs exhibit different molecular pattern with respect to non-CSCs. They maintain their stemness and chemoresistant features through specific signaling cascades. CSCs are weak in immunogenicity and act as immunosupressor in the host system. Melanoma treatment becomes difficult and survival is greatly reduced when the patient develop metastasis. Standard conventional oncology treatments such as chemotherapy, radiotherapy and surgical resection are only responsible for shrinking the bulk of the tumor mass and tumor tends to relapse. Thus, targeting CSCs and their microenvironment niche addresses the alternative of traditional cancer therapy. Combined use of CSCs targeted and traditional therapies may kill the bulk tumor and CSCs and offer a promising therapeutic strategy for the management of melanoma.
Bcl6 as a Novel Therapeutic Target in Multiple Myeloma (MM).
Authors: Teru Hideshima, Constantine S. Mitsiades, Hiroshi Ikeda, Dharminder Chauhan, Noopur Raje, Gullu Gorgun, Mariateresa Fulciniti, Diana Cirstea, Giulia Perron, Loredana Santo, Ayaka Hideshima, Klaus Podar, Nikhil C. Munshi, Paul Richardson, Daniel R. Carrasco, Kenneth C. Anderson
Journal: Blood (2009)
Defining the Added Value of 99mTc-MIBI SPECT/CT to Conventional Cross-Sectional Imaging in the Characterization of Enhancing Solid Renal Masses
Authors: Sara Sheikhbahaei, Christopher S. Jones, Kristin K. Porter, Steven P. Rowe, Michael A. Gorin, Alex S. Baras, Phillip M. Pierorazio, Mark W. Ball, Takahiro Higuchi, Pamela T. Johnson, Lilja B. Solnes, Jonathan I. Epstein, Mohamad E. Allaf, Mehrbod S. Javadi
Journal: Clinical Nuclear Medicine (2017)

Purpose This study investigates whether the addition of preoperative 99mTc-MIBI SPECT/CT can increase the degree of diagnostic confidence in the differentiation of benign from malignant enhancing renal masses. Patients and Methods Patients were recruited as part of an institutional review board–approved prospective clinical trial. Forty-eight patients with clinical stage T1 solid renal masses who underwent a 99mTc-MIBI SPECT/CT before partial or radical nephrectomy were evaluated. Conventional CT and MRI, which were approximately performed within 8 weeks before 99mTc-MIBI, were retrospectively retrieved. Based on a 5-point scale (1 = definitely benign, 5 = definitely malignant), 2 blinded readers recorded their degree of confidence for each lesion using conventional imaging before and after reviewing the 99mTc-MIBI uptake ratios. Surgical pathology was considered as the reference standard. Results Additional review of 99mTc-MIBI SPECT/CT uptake ratios increased diagnostic confidence in the differentiation of solid renal masses in 14/48 lesions (29.2%). In 9 lesions, the addition of 99mTc-MIBI changed the initial confidence levels of malignancy toward benign diagnosis. Postsurgical pathology confirmed the diagnosis of benign histology (oncocytoma/hybrid oncocytic-chromophobe tumors) in 7 and chromophobe renal cell carcinoma (behave as indolent) in 2 of these lesions. 99mTc-MIBI increased the confidence level toward malignancy in 5 cases; all were confirmed as RCC on surgical pathology. The area under the receiver operative characteristic curve was 0.60 for conventional imaging alone and 0.85 after reviewing 99mTc-MIBI (P for difference = 0.03). Conclusions Preoperative 99mTc-MIBI SPECT/CT enhances the performance of conventional imaging, improving the characterization of benign histologies and lowering the possibility of misclassification.
The treatment of esophageal cancer by vascular-targeted photodynamic therapy (VTP) using orthotopic rat model.
Authors: Ronny Uzana, Dina Preise, Lilach Agemy, Rachel Elmoalem, Alexander Brandis, Varda Belkin, Yoram Salomon, Avigdor Scherz
Journal: Journal of Clinical Oncology (2015)

91 Background: Vascular targeted photodynamic therapy (VTP) based on local sensitization of circulating WST11, a water-soluble derivative of Pd-bacteriochlorophyll, enables effective focal ablation of solid tumors. Highly toxic oxygen radicals are produced in the vascular lumen upon illumination with near infra-red light (755nm), leading to irreversible occlusion of tumor feeding arteries and veins. WST11 clears rapidly from the circulation and does not accumulate in the body, providing high level of safety and minimizing adverse effects. WST11-VTP completed Phase II clinical trials in USA and Phase III in Europe for the treatment of early localized prostate cancer as a first line monotherapy with above 80% complete response rate. Here we evaluate its’ safety and efficacy for the treatment of esophageal cancer aiming at development of clinically translatable treatment protocol. Methods: We developed an orthotopic model in which esophageal cancer cells are implanted in the mid esophagus using endoscopy guided procedure. Established tumors are illuminated with cylindrical diffuser deployed through the custom built endoscopy guided system following infusion of WST11. For assessment of treatment safety and tissue recovery normal esophagus tissue was subjected to WST11-VTP using the same treatment set up. Selectivity and efficacy were evaluated histologically by examining sections of treated tumors and normal esophageal tissues under various treatment conditions. Results: Safety control VTP procedures on healthy esophageal tissues have shown a confined destruction only at the illuminated zone while collateral damage to neighboring tissues was not observed. The impact runs as deep as the muscularis propria without signs of perforation or death as a result of the procedure. The VTP protocol was able to ablate implanted and established tumors as opposed to the control group with light illumination alone without the sensitizer (WST11). Conclusions: VTP could be safely applied to treat esophageal tumors, with transient and mild adverse effects. Importantly, VTP effectively eradicated established esophageal tumors in tested set up that could be translated into a clinical treatment protocol.
High Avidity HLA-A2-Restricted CD8+ T Cells against the Wilms Tumor Protein (WT1) Can Be Isolated Only from HLA-A2 Negative Donors Not Subjected to HLA-A2-Mediated Thymic Deletion
Authors: Inge Jedema, Marian van de Meent, Willem J.J. Falkenburg, Michel G.D. Kester, Roel Willemze, J.H. Frederik Falkenburg
Journal: Blood (2008)
Dispersal of Therapeutic Donor Cells throughout the Brain of Mice with Lysosomal Storage Disease Occurs Following in Utero Transplantation of Fetal-Derived Neuronal Stem Cells.
Authors: Brian W. Soper, C. Bruce Anthony, Anna-Michelle Dendi-Young, Mark D. Lessard, Travis L. Alley, Jennifer L. Proctor, Jane E. Barker
Journal: Blood (2004)
Generalizing about Public Health Interventions: A Mixed-Methods Approach to External Validity
Authors: Laura C. Leviton
Journal: Annual Review of Public Health (2017)

Public health researchers and practitioners are calling for greater focus on external validity, the ability to generalize findings of evidence-based interventions (EBIs) beyond the limited number of studies testing effectiveness. For public health, the goal is applicability: to translate, disseminate, and implement EBIs for an impact on population health. This article is a review of methods and how they might be combined to better assess external validity. The methods include (a) better description of EBIs and their contexts; (b) combining of statistical tools and logic to draw inferences about study samples; (c) sharper definition of the theory behind the intervention and core intervention components; and (d) more systematic consultation of practitioners. For population impact, studies should focus on context features that are likely to be both important (based on program theory) and frequently encountered by practitioners. Mixed-method programs of research will allow public health to expand causal generalizations.
OS5.7 First results of the randomized phase II TAVAREC trial on temozolomide with or without bevacizumab in 1p/19q intact 1st recurrence grade II and III glioma
Authors: A. Idbaih, P. M. Clement, F. Y. F. Vos, M. Platten, P. Mulholland, M. J. B. Taphoorn, L. Lewis, V. Golfinopoulos, T. Gorlia, M. J. van den Bent
Journal: Neuro-Oncology (2016)

lesions and discarded non-enhancing high grade lesions.This selection does not represent the actual clinical situation in which a clinician is confronted with a LGG-like lesion on MRI that is eligible for extensive resection.Therefore a study with patient selection based on preoperative characteristics is more clinically relevant.We conducted a retrospective study to examine if early resection improved overall survival (OS) compared to wait-and-scan or a biopsy for LGG-like lesions that were eligible for extensive resection.MATERIALS AND METHODS: We searched the records of all glioma patients (both low and high-grade) in three large neurosurgical institutions in the Netherlands between 1990-2010.From this set of 1115 patients, images in 498 patients were available.To identify patients with a LGG-like lesion that was eligible for extensive resection, we screened for well-known prognostic favorable characteristics; i.e. supratentorial, non-enhancing lesion with <6 cm maximal diameter and only epilepsy or minimal neurological deficits.Based on these criteria, a total of 150 patients were identified.OS was used as primary outcome measure.Median follow-up was.7.1 years.RESULTS: As initial treatment strategy, patients underwent either an early resection (n=83), a wait-and-scan approach (n=38) or a biopsy (n=29).Clinical and tumor characteristics were evenly distributed, except for histology and grade: the biopsy group consisted of more astrocytomas (75.9% vs 48.2% in resection and 42.1% in wait-and-scan; P=0.01) and the wait-andscan group consisted of more higher grade gliomas (24.3% vs 10.8% in resection and 3.4% in biopsy; P=0.04).The latter can be expected, since histological diagnosis in the wait-and-scan group was obtained after a median of 2.95 years from initial imaging diagnosis.Median OS was not reached in the resection group, 11.9 years in the wait-and-scan group and 9.1 years in the biopsy group.There was no difference in OS for early resection versus wait-and-scan with a hazard ratio (HR) of 0.92 (95% CI 0.43-2.01;P=0.85).However, the biopsy group showed a significant shorter OS compared to early resection and wait-and-scan (HR 2.69; 95% CI 1.19-6.06;P=0.02).CONCLUSIONS: We observed no difference in OS for early resection versus an initial wait-and-scan approach.This suggests that wait-and-scan is safe and as effective as early resection for patients with minimal neurological deficits and small LGG-like lesions eligible for extensive resection.Our data argue against biopsy as initial strategy for LGG patients.This, however, is difficult to explain and needs further investigation. OS5
The Use of Recombinant Human Erythropoietin (rHuEpo) after Reduced Intensity Conditioning (RIC) Allogeneic Hematopoietic Peripheral Blood Stem Cell Transplantation (ASCT) Reduce Red Blood Cell (RBC) Transfusion Requirements.
Authors: Vadim Ivanov, Jean El Cheikh, Catherine Faucher, Sabine Furst, Mohamad Mohty, Patrick Ladaique, Claude Lemarie, Aude Charbonnier, Diane Coso, Jean Marc Schiano, Frederic Viret, Didier Blaise
Journal: Blood (2006)
Initial Clinical Validation of a Rapid, Low-Cost, Paper-Based Diagnostic Test for Sickle Cell Anemia As a Tool to Facilitate Newborn Screening in Resource-Limited Settings
Authors: Nathaniel Z. Piety, Alex George, Sonia Serrano, Maria Rosa Lanzi, Palka R. Patel, Maria Paz Noli, Damian Nirenberg, Joao Camanda, Gladstone Airewele, Sergey S. Shevkoplyas
Journal: Blood (2015)
New Aspects on the Safety of Multidrug-Resistance 1 Gene Transfers: No Indication for Clonal Dominance after Long-Term Follow-Up in a Primate Transplantation Model.
Authors: Farastuk Bozorgmehr, Eike C. Buss, Stephanie Laufs, K. Zsuzsanna Nagy, Stephanie Sellers, W. Jens Zeller, Cynthia E. Dunbar, Stefan Fruehauf
Journal: Blood (2004)
CD34+-Selected Infusions of Fresh or Cryopreserved Peripheral Blood Stem Cells for the Treatment of Poor Graft Function Following Allogeneic Hematopoietic Stem Cell Transplant
Authors: Armin Ghobadi, Mark A Fiala, Giridharan Ramsingh, Feng Gao, Camille N. Abboud, Keith Stockerl-Goldstein, Geoffrey L. Uy, Peter Westervelt, John F. DiPersio
Journal: Blood (2015)
Quantitative Clonal Dynamics Define Mechanisms of CLL Evolution in Response to Combination Chemotherapy
Authors: Dan A. Landau, Eugen Tausch, Sebastian Böttcher, Chip Stewart, Ivana Bozic, Iganty Leischner, Daniel Rosebrock, Amaro Taylor-Weiner, Daniel Mertens, Carrie Sougnez, Sabrina Kless, Michael Kneba, Matthias Ritgen, Sandra Kluth, Jasmin Bahlo, Anna-Maria Fink, Kirsten Fischer, Stacey Gabriel, Eric Lander, Hartmut Dohner, Michael Hallek, Donna S Neuberg, Martin Nowak, Gad Getz, Stephan Stilgenbauer, Catherine J. Wu
Journal: Blood (2015)
A Five Parameter Based Flow Cytometric Scoring System Refines the Revised International Prognostic Scoring System for Myelodysplastic Syndromes
Authors: Canan Alhan, Theresia M. Westers, Eline M.P. Cremers, Claudia Cali, Gert J Ossenkoppele, Arjan A. van de Loosdrecht
Journal: Blood (2012)
Amphiregulin Is Produced by Myeloma Cells and Is Involved in Tumor-Environment Interactions in Multiple Myeloma.
Authors: Karène Mahtouk, Dirk Hose, Thierry Reme, John De Vos, Michel Jourdan, Jérome Moreaux, Geneviève Fiol, Marc Raab, Eric Jourdan, Marion Moos, Hartmut Goldschmidt, Jean-François Rossi, Friedrich W. Cremer, Bernard Klein
Journal: Blood (2004)
Disruption of CTNNB1/LEF-1 Complex by Small Molecule Inhibitors Induces Apoptosis in B-CLL Cells in Vitro and in Vivo
Authors: Rajesh Kumar Gandhirajan, Iris Gehrke, Julian Paesler, Regina Razavi, Alexandra Filipovich, Felix Erdfelder, Magdalena Hertweck, Guenter Plickert, Esther Katharina Schmitt, Axel Schlösser, Michael Hallek, Karl Anton Kreuzer
Journal: Blood (2008)
A Randomized Phase II Study Evaluating the Efficacy, Safety and Cost-Effectiveness of Pegfilgrastim and Filgrastim After High Dose Chemotherapy and Autologous Stem Cell Transplantation In Patients with Lymphoma and Myeloma (PALM Study).
Authors: Catherine Sebban, Anne Lefranc, Lionel Perrier, Philippe Moreau, Daniel Espinouse, Marie Pierre Moles-Moreau, Leila Kammoun, Herve Ghesquieres, Celine Segura-Ferlay, Jacques-Olivier Bay, Severine Lissandre, David Pérol, Mauricette Michallet, Philippe Quittet
Journal: Blood (2010)
Unfolding anti-tumor immunity: ER stress responses sculpt tolerogenic myeloid cells in cancer
Authors: Juan R. Cubillos-Ruiz, Eslam Mohamed, Paulo C. Rodriguez
Journal: Journal for ImmunoTherapy of Cancer (2017)

Established tumors build a stressful and hostile microenvironment that blocks the development of protective innate and adaptive immune responses. Different subsets of immunoregulatory myeloid populations, including dendritic cells, myeloid-derived suppressor cells (MDSCs) and macrophages, accumulate in the stressed tumor milieu and represent a major impediment to the success of various forms of cancer immunotherapy. Specific conditions and factors within tumor masses, including hypoxia, nutrient starvation, low pH, and increased levels of free radicals, provoke a state of "endoplasmic reticulum (ER) stress" in both malignant cells and infiltrating myeloid cells. In order to cope with ER stress, cancer cells and tumor-associated myeloid cells activate an integrated signaling pathway known as the Unfolded Protein Response (UPR), which promotes cell survival and adaptation under adverse environmental conditions. However, the UPR can also induce cell death under unresolved levels of ER stress. Three branches of the UPR have been described, including the activation of the inositol-requiring enzyme 1 (IRE1), the pancreatic ER kinase (PKR)-like ER kinase (PERK), and the activating transcription factor 6 (ATF6). In this minireview, we briefly discuss the role of ER stress and specific UPR mediators in tumor development, growth and metastasis. In addition, we describe how sustained ER stress responses operate as key mediators of chronic inflammation and immune suppression within tumors. Finally, we discuss multiple pharmacological approaches that overcome the immunosuppressive effect of the UPR in tumors, and that could potentially enhance the efficacy of cancer immunotherapies by reprogramming the function of tumor-infiltrating myeloid cells.
Memory Phenotype CD8+T Cells Are Superior to Naive CD8+T Cells in Separating Graft Anti-Tumor Activity From Gvhd After Bone Marrow Transplantation; Application to DLI.
Authors: Suparna Dutt, Jeanette Baker, Neeraja Kambham, Holbrook E Kohrt, Robert Negrin, Samuel Strober
Journal: Blood (2009)
Building and Clinical Use of Activated Plasma Clotting Time Test and the Value of APCT on Predicting the Bleeding Due to Leukemia Chemotherapy-Induced Thrombocytopenia.
Authors: Bao-An Chen, Jin-Jin Li, Cheng-Yin Huang, Feng Gao, Jian Chen, Chong Gao, Yun-Yu Sun, Jun Wang, Gang Zhao, Jia-Hua Ding, Ning-Na Chen, Xiao-Ping Pei
Journal: Blood (2007)